CML-395 Efficacy and Safety Results From ASCEMBL, a Phase III Study of Asciminib vs. Bosutinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) After ≥2 Prior Tyrosine Kinase Inhibitors (TKIs): Week 96 Update

1. Réa, D.
2. Hochhaus, A.
3. Mauro, M.J.
4. Minami, Y.
5. Lomaia, E.
6. Voloshin, S.
7. Turkina, A.
8. Kim, D.-W.
9. Apperley, J.F.
10. Cortes, J.E.
11. Abdo, A.
12. Fogliatto, L.M.
13. Kim, D.D.H.
14. Coutre, P.L.
15. Saussele, S.
16. Annunziata, M.
17. Hughes, T.P.
18. Chaudhri, N.
19. Chee, L.
20. García-Gutiérrez, V.
21. Sasaki, K.
22. Kapoor, S.
23. Allepuz, A.
24. Quenet, S.
25. Bédoucha, V.
26. Boquimpani, C.
27. Mostrar todos los/as autores/as +